Abstract
In a cohort of 534 patients treated for Mycobacterium avium complex pulmonary disease, those who failed to achieve culture conversion were older, had higher proportions of males and cavity presence, were more likely to receive clofazimine and aminoglycosides, but less likely to receive rifampicin, and had a shorter overall treatment duration. Time-varying analysis of individual drug effects on time to culture conversion identified rifampicin as being associated with a reduced culture conversion rate (adjusted hazard ratio, 0.959; 95% confidence interval, .924–.995; P = .027), suggesting a potentially negative effect on Mycobacterium avium complex pulmonary disease outcomes, whereas other drugs showed no significant association.
| Original language | English |
|---|---|
| Article number | ofaf138 |
| Journal | Open Forum Infectious Diseases |
| Volume | 12 |
| Issue number | 3 |
| DOIs | |
| State | Published - 1 Mar 2025 |
Bibliographical note
Publisher Copyright:© The Author(s) 2025. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- antibiotic
- nontuberculous mycobacteria
- respiratory infection
- rifampicin
- time-varying
Fingerprint
Dive into the research topics of 'Effect of Individual Agents on Time to Culture Conversion in Mycobacterium avium Complex Pulmonary Disease'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver